Kara Higgins

803 total citations
7 papers, 119 citations indexed

About

Kara Higgins is a scholar working on Genetics, Pathology and Forensic Medicine and Gastroenterology. According to data from OpenAlex, Kara Higgins has authored 7 papers receiving a total of 119 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 5 papers in Pathology and Forensic Medicine and 2 papers in Gastroenterology. Recurrent topics in Kara Higgins's work include Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (5 papers) and Gastrointestinal Tumor Research and Treatment (2 papers). Kara Higgins is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (5 papers) and Gastrointestinal Tumor Research and Treatment (2 papers). Kara Higgins collaborates with scholars based in United States, Italy and Canada. Kara Higgins's co-authors include Arnon P. Kater, Asher Chanan‐Khan, John F. Seymour, Paolo Ghia, Anthony R. Mato, Wojciech Jurczak, Richard R. Furman, Stephan Stilgenbauer, Jennifer R. Brown and Jennifer A. Woyach and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Kara Higgins

7 papers receiving 119 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kara Higgins United States	4	102	90	33	28	24	7	119
Éric Durot France	6	65 0.6×	74 0.8×	21 0.6×	16 0.6×	22 0.9×	26	92
Tommi Salmi United States	5	86 0.8×	75 0.8×	17 0.5×	24 0.9×	23 1.0×	11	96
Gayane Tumyan Russia	5	56 0.5×	75 0.8×	60 1.8×	10 0.4×	22 0.9×	22	117
M Asuncion Echeveste Spain	3	61 0.6×	46 0.5×	8 0.2×	29 1.0×	16 0.7×	4	75
Yufu Lin China	3	50 0.5×	35 0.4×	22 0.7×	18 0.6×	28 1.2×	10	81
Edyta Subocz Poland	7	34 0.3×	46 0.5×	14 0.4×	22 0.8×	9 0.4×	16	88
Michael Aßmann Germany	5	45 0.4×	62 0.7×	56 1.7×	13 0.5×	6 0.3×	11	101
Mariya Salman United Kingdom	5	87 0.9×	83 0.9×	9 0.3×	36 1.3×	14 0.6×	12	91
G. Barosi Italy	6	50 0.5×	37 0.4×	23 0.7×	41 1.5×	5 0.2×	11	101
Marina Deodato Italy	6	75 0.7×	53 0.6×	15 0.5×	18 0.6×	22 0.9×	13	99

Countries citing papers authored by Kara Higgins

Since Specialization

Citations

This map shows the geographic impact of Kara Higgins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kara Higgins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kara Higgins more than expected).

Fields of papers citing papers by Kara Higgins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kara Higgins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kara Higgins. The network helps show where Kara Higgins may publish in the future.

Co-authorship network of co-authors of Kara Higgins

This figure shows the co-authorship network connecting the top 25 collaborators of Kara Higgins. A scholar is included among the top collaborators of Kara Higgins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kara Higgins. Kara Higgins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Seymour, John F., John C. Byrd, Paolo Ghia, et al.. (2023). Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 142(8). 687–699. 62 indexed citations

2.

Seymour, John F., John C. Byrd, Talha Munir, et al.. (2022). Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL). Blood. 140(Supplement 1). 7050–7052. 2 indexed citations

3.

Budde, Lihua E., Morton Coleman, Don A. Stevens, et al.. (2022). Acalabrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): Results of a phase 2, multicenter, open-label trial.. Journal of Clinical Oncology. 40(16_suppl). 7549–7549. 1 indexed citations

4.

Strati, Paolo, Morton Coleman, Shuo Ma, et al.. (2022). A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. British Journal of Haematology. 199(1). 76–85. 22 indexed citations

5.

Strati, Paolo, Beth Christian, Peter Martin, et al.. (2022). Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, Open-Label, Phase 1b Trial. Blood. 140(Supplement 1). 3606–3608. 5 indexed citations

6.

Seymour, John F., John C. Byrd, Peter Hillmen, et al.. (2021). Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL). Blood. 138(Supplement 1). 3721–3721. 1 indexed citations

7.

Byrd, John C., Peter Hillmen, Paolo Ghia, et al.. (2021). First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.. Journal of Clinical Oncology. 39(15_suppl). 7500–7500. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact